Drug Combination Details

General Information of the Combination (ID: C47203)
Name Paclitaxel   NP Info  + Napabucasin   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Phase 3 [1]
Ovarian cancer [ICD-11: 2C73]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation STAT3  Molecule Info 
Pathway MAP
                    In-vitro Model A2780 CVCL_0134 Ovarian endometrioid adenocarcinoma Homo sapiens
SK-OV-3 CVCL_0532 Ovarian serous cystadenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Paclitaxel combined BBI608 results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
References
Reference 1 ClinicalTrials.gov (NCT02826161) A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L).
Reference 2 Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden. Cell Prolif. 2020 Jan;53(1):e12719.
 Download Picture         KEGG Link